Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.
A next-generation cancer drug combined with chemotherapy works better in lymphoma patients whose tumors carry specific genetic changes.
This phase II study evaluated the next-generation BTK inhibitor zanubrutinib combined with R-CHOP in previously untreated DLBCL patients selected for BTK pathway gene alterations. Results support the biomarker-directed combination approach for this molecularly defined subgroup, warranting phase III investigation.
What the study was
- Study design
- Phase II Clinical Trial
- Population
- Previously untreated DLBCL with BTK pathway gene alterations
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Blood cancer journal
Why it surfaced
Blood Cancer Journal Phase II trial; zanubrutinib+R-CHOP in BTK-pathway-selected DLBCL is a precision hematology advance; supports biomarker-directed first-line intensification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.